Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Jan 19, 2022 · Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Mar 27, 2023 · Pembrolizumab in combination with lenvatinib has shown efficacy in pMMR, microsatellite-stable endometrial cancer. 10-12.
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced ...
Apr 14, 2023 · In total, 827 patients with advanced, recurrent, or metastatic endometrial cancer (EC) were randomly assigned to receive lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks (n = 411) or chemotherapy of the treating physician's choice (doxorubicin 60 mg/m 2 intravenously once every 3 weeks or paclitaxel ...
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Mar 13, 2020 · Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile. View transcript. Introduction.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Feb 3, 2022 · Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer. (Funded by Eisai and Merck Sharp and Dohme [a subsidiary of Merck]; Study 309-KEYNOTE-775 ClinicalTrials.gov number, NCT03517449 ….
Lenvatinib plus pembrolizumab in patients with advanced endometrial …
Mar 25, 2019 · Pembrolizumab, an antibody targeting PD-1, has moderate efficacy in biomarker-unselected endometrial cancer. We aimed to assess the combination of lenvatinib plus pembrolizumab in patients with advanced endometrial carcinoma, after establishing the maximum tolerated dose in a phase 1b study.
FDA grants regular approval to pembrolizumab and lenvatinib …
Feb 1, 2022 · On July 21, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that...
CONCLUSION Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity prole. fi.
Survival benefit with second-line combination in endometrial cancer ...
Jan 27, 2022 · In July 2021, the FDA approved lenvatinib plus pembrolizumab for patients with advanced-stage endometrial cancer that is not mismatch-repair-deficient or microsatellite instability-high. Data...
Lenvatinib Combo Prolongs OS, PFS in Advanced Endometrial Cancer …
Mar 19, 2024 · Combining lenvatinib (Lenvima) with pembrolizumab (Keytruda) improved overall survival (OS) and progression-free survival (PFS) compared with chemotherapy across most patients with advanced/recurrent endometrial cancer.